Alnylam commences underwritten public offering of 7.
Alnylam commences underwritten public offering of 7,000,000 shares of common stock Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, today announced that it provides commenced an underwritten public offering of 7,000,000 shares of its common stock http://www.cialiscanada.info/reviews.html . All of these shares are for sale by Alnylam. J.P. Morgan Securities LLC is usually acting as sole book-running supervisor for the proposed providing. Alnylam intends to grant the underwriter a 30-day option to purchase up to an additional 1,050,000 shares to cover overallotments, if any.
Musculoskeletal pain can be an extremely frequent symptom. In fact, the EPIDOR study showed that pain is undoubtedly the biggest symptom in rheumatology consultations. This research discovered that 99 percent of individuals who go to a rheumatologist for the very first time and 95 percent of those who go for a follow-up visit had suffered some form of discomfort in the week prior to their visit.. Almost half of all adolescents suffer low back pain A report led by Catalan researchers confirms that 40 percent of adolescents possess low back pain at least once a month.